Form 4: Enliven Therapeutics CSO Sells 5,000 Shares

Enliven Therapeutics' Chief Scientific Officer, Joseph P Lyssikatos, sold 5,000 shares of common stock for a weighted average price of $29.0438 per share.

Summary

• Joseph P Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), reported a sale of common stock.
• The transaction involved the disposition of 5,000 shares of common stock.
• The shares were sold on February 6, 2026, at a weighted average price of $29.0438 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.
• Following this transaction, Lyssikatos beneficially owns 740,188 shares, held indirectly through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned under a 10b5-1 plan, indicating a structured personal financial decision rather than an immediate reaction to company-specific news.

Future Outlook

The filing, an insider transaction report, does not provide any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider sales, even those pre-planned under Rule 10b5-1, are routinely monitored by investors for potential signals regarding management's confidence in the company's future prospects. This specific transaction by a Chief Scientific Officer in a biotech company like Enliven Therapeutics could be viewed in the context of personal financial planning rather than a direct reflection on the company's operational performance or drug pipeline.

Stakeholder Impact

• Shareholders might interpret insider selling, even if pre-planned, with caution, though the impact is likely minimal given the Rule 10b5-1 plan.

Key Dates

Recommendation

The sale by the Chief Scientific Officer was executed under a pre-arranged Rule 10b5-1 trading plan, suggesting a planned personal financial event rather than a reaction to new company developments. This type of transaction generally does not provide a strong signal for a change in investment strategy for Enliven Therapeutics.

Keywords

Enliven Therapeutics, ELVN, Joseph P Lyssikatos, insider trading, Form 4, stock sale, 10b5-1 plan, Chief Scientific Officer